Matches in Wikidata for { <http://www.wikidata.org/entity/Q99710335> ?p ?o ?g. }
Showing items 1 to 46 of
46
with 100 items per page.
- Q99710335 description "article scientifique publié en 2020" @default.
- Q99710335 description "artículu científicu espublizáu en setiembre de 2020" @default.
- Q99710335 description "scientific article published on 21 September 2020" @default.
- Q99710335 description "wetenschappelijk artikel" @default.
- Q99710335 description "наукова стаття, опублікована 21 вересня 2020" @default.
- Q99710335 name "Results from phase II, open-label study of anti-tumoral activity of first-line erlotinib in advanced/metastatic NSCLC patients with EGFR activating mutations, in Portugal: The MuTAR study" @default.
- Q99710335 name "Results from phase II, open-label study of anti-tumoral activity of first-line erlotinib in advanced/metastatic NSCLC patients with EGFR activating mutations, in Portugal: The MuTAR study" @default.
- Q99710335 type Item @default.
- Q99710335 label "Results from phase II, open-label study of anti-tumoral activity of first-line erlotinib in advanced/metastatic NSCLC patients with EGFR activating mutations, in Portugal: The MuTAR study" @default.
- Q99710335 label "Results from phase II, open-label study of anti-tumoral activity of first-line erlotinib in advanced/metastatic NSCLC patients with EGFR activating mutations, in Portugal: The MuTAR study" @default.
- Q99710335 prefLabel "Results from phase II, open-label study of anti-tumoral activity of first-line erlotinib in advanced/metastatic NSCLC patients with EGFR activating mutations, in Portugal: The MuTAR study" @default.
- Q99710335 prefLabel "Results from phase II, open-label study of anti-tumoral activity of first-line erlotinib in advanced/metastatic NSCLC patients with EGFR activating mutations, in Portugal: The MuTAR study" @default.
- Q99710335 P1433 Q99710335-E06C18BD-8854-4168-BAFD-B824CB7DC48F @default.
- Q99710335 P1476 Q99710335-3B0E2CAE-35F5-41B5-A928-14FDB307CEC1 @default.
- Q99710335 P2093 Q99710335-08548033-C1FA-4950-8F83-9B300651FD46 @default.
- Q99710335 P2093 Q99710335-21D9F9E8-FE98-45A2-BDEE-B28DDB524AEA @default.
- Q99710335 P2093 Q99710335-2B1B7667-D40E-41F1-9584-19F07DBE5659 @default.
- Q99710335 P2093 Q99710335-2E484168-8B0A-43E7-BBBF-90C4DDDB9AEE @default.
- Q99710335 P2093 Q99710335-64D7AFA8-3B96-4089-B29D-57F0862FB3BF @default.
- Q99710335 P2093 Q99710335-8C206397-B954-475C-BE78-637E02EFB712 @default.
- Q99710335 P2093 Q99710335-DA8F3ADA-4C54-433C-8B04-E865748E84A2 @default.
- Q99710335 P2093 Q99710335-E199644F-2D8A-440B-A8CF-016E282A5BAE @default.
- Q99710335 P2093 Q99710335-ED1C359E-ECDE-453D-9A7D-C5CAB6733EBB @default.
- Q99710335 P31 Q99710335-F286E789-2464-46CE-8BF7-C444E307DE57 @default.
- Q99710335 P356 Q99710335-28C74961-BE26-44E0-B9BA-A5CA9861C325 @default.
- Q99710335 P577 Q99710335-E7229428-8E8D-4B05-AF6C-CC3927891186 @default.
- Q99710335 P698 Q99710335-2D000C8F-D5A3-4735-A361-2D1A75E8A166 @default.
- Q99710335 P921 Q99710335-A208D731-8E5C-4FEF-BDCD-B4927F33923D @default.
- Q99710335 P356 J.PULMOE.2020.08.007 @default.
- Q99710335 P698 32972881 @default.
- Q99710335 P1433 Q96320391 @default.
- Q99710335 P1476 "Results from phase II, open-label study of anti-tumoral activity of first-line erlotinib in advanced/metastatic NSCLC patients with EGFR activating mutations, in Portugal: The MuTAR study" @default.
- Q99710335 P2093 "A Antunes" @default.
- Q99710335 P2093 "B Parente" @default.
- Q99710335 P2093 "E Teixeira" @default.
- Q99710335 P2093 "F Barata" @default.
- Q99710335 P2093 "H Queiroga" @default.
- Q99710335 P2093 "J C Mellidez" @default.
- Q99710335 P2093 "M Soares" @default.
- Q99710335 P2093 "P Alves" @default.
- Q99710335 P2093 "T Almodovar" @default.
- Q99710335 P31 Q13442814 @default.
- Q99710335 P356 "10.1016/J.PULMOE.2020.08.007" @default.
- Q99710335 P577 "2020-09-21T00:00:00Z" @default.
- Q99710335 P698 "32972881" @default.
- Q99710335 P921 Q3658562 @default.